<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-9-217</article-id><article-id pub-id-type="pmid">19570204</article-id><article-id pub-id-type="doi">10.1186/1471-2407-9-217</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Prognostic relevance of Wnt-inhibitory factor-1 (<italic>WIF1</italic>) and Dickkopf-3 (<italic>DKK3</italic>) promoter methylation in human breast cancer</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Veeck</surname><given-names>J&#x000fc;rgen</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I5">5</xref><email>juergen.veeck@rwth-aachen.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Wild</surname><given-names>Peter J</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>peter.wild@cell.biol.ethz.ch</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Fuchs</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>thomas.fuchs@inf.ethz.ch</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Sch&#x000fc;ffler</surname><given-names>Peter J</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>peter.schueffler@inf.ethz.ch</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Hartmann</surname><given-names>Arndt</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>arndt.hartmann@uk-erlangen.de</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Kn&#x000fc;chel</surname><given-names>Ruth</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>rknuechel-clarke@ukaachen.de</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Dahl</surname><given-names>Edgar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>edahl@ukaachen.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Molecular Oncology Group, Institute of Pathology, University Hospital of the RWTH Aachen, Pauwelsstrasse 30, D-52074 Aachen, Germany</aff><aff id="I2"><label>2</label>Institute of Surgical Pathology, University Hospital Z&#x000fc;rich, Schmelzbergstrasse 12, CH-8091, Z&#x000fc;rich, Switzerland</aff><aff id="I3"><label>3</label>Institute for Computational Science and Department of Computer Science, ETH Z&#x000fc;rich, Universit&#x000e4;tsstrasse 6, CH-8092 Z&#x000fc;rich, Switzerland</aff><aff id="I4"><label>4</label>Department of Pathology, University of Erlangen, Krankenhausstrasse 12, D-91054 Erlangen, Germany</aff><aff id="I5"><label>5</label>Current address: Cancer Epigenetics and Biology Program (PEBC), Bellvitge Institute for Biomedical Research (ICO-IDIBELL), Hospital Duran i Reynals, Av. Gran Via de L'Hospitalet 199-203, E-08907 Barcelona, Spain</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>1</day><month>7</month><year>2009</year></pub-date><volume>9</volume><fpage>217</fpage><lpage>217</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/217"/><history><date date-type="received"><day>8</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>1</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Veeck et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Veeck et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Veeck J&#x000fc;rgen juergen.veeck@rwth-aachen.de </dc:author><dc:title> Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Cancer 9(1): 217-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2009)9:1&#x0003c;217&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Secreted Wnt signaling antagonists have recently been described as frequent targets of epigenetic inactivation in human tumor entities. Since gene silencing of certain Wnt antagonists was found to be correlated with adverse patient survival in cancer, we aimed at investigating a potential prognostic impact of the two Wnt antagonizing molecules <italic>WIF1 </italic>and <italic>DKK3 </italic>in breast cancer, which are frequently silenced by promoter methylation in this disease.</p></sec><sec sec-type="methods"><title>Methods</title><p><italic>WIF1 </italic>and <italic>DKK3 </italic>promoter methylation were assessed by methylation-specific PCR with bisulfite-converted DNA from 19 normal breast tissues and 150 primary breast carcinomas. Promoter methylation was interpreted in a qualitative, binary fashion. Statistical evaluations included two-sided Fisher's exact tests, univariate log-rank tests of Kaplan-Meier curves as well as multivariate Cox regression analyses.</p></sec><sec><title>Results</title><p><italic>WIF1 and DKK3 </italic>promoter methylation were detected in 63.3% (95/150) and 61.3% (92/150) of breast carcinoma samples, respectively. In normal breast tissues, <italic>WIF1 </italic>methylation was present in 0% (0/19) and <italic>DKK3 </italic>methylation in 5.3% (1/19) of samples. In breast carcinomas, <italic>WIF1 </italic>methylation was significantly associated with methylation of <italic>DKK3 </italic>(p = 0.009). Methylation of either gene was not associated with clinicopathological parameters, except for <italic>DKK3 </italic>methylation being associated with patient age (p = 0.007). In univariate analysis, <italic>WIF1 </italic>methylation was not associated with clinical patient outcome. In contrast, <italic>DKK3 </italic>methylation was a prognostic factor in patient overall survival (OS) and disease-free survival (DFS). Estimated OS rates after 10 years were 54% for patients with <italic>DKK3</italic>-methylated tumors, in contrast to patients without <italic>DKK3 </italic>methylation in the tumor, who had a favorable 97% OS after 10 years (p &#x0003c; 0.001). Likewise, DFS at 10 years for patients harboring <italic>DKK3 </italic>methylation in the tumor was 58%, compared with 78% for patients with unmethylated <italic>DKK3 </italic>(p = 0.037). Multivariate analyses revealed that <italic>DKK3 </italic>methylation was an independent prognostic factor predicting poor OS (hazard ratio (HR): 14.4; 95% confidence interval (CI): 1.9&#x02013;111.6; p = 0.011), and short DFS (HR: 2.5; 95% CI: 1.0&#x02013;6.0; p = 0.047) in breast cancer.</p></sec><sec><title>Conclusion</title><p>Although the Wnt antagonist genes <italic>WIF1 </italic>and <italic>DKK3 </italic>show a very similar frequency of promoter methylation in human breast cancer, only <italic>DKK3 </italic>methylation proves as a novel prognostic marker potentially useful in the clinical management of this disease.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The most common epigenetic alteration in human cancer affecting gene expression is 5'-cytosine methylation within CpG islands in gene promoter regions [<xref ref-type="bibr" rid="B1">1</xref>]. Promoter methylation effectively represses RNA transcription and occurs in many genes involved in human cancer development [<xref ref-type="bibr" rid="B2">2</xref>]. The majority of these affected genes are potential or known tumor suppressor genes that are regulators of different cellular pathways, such as cell cycle, DNA repair, growth factor signaling or cell adhesion [<xref ref-type="bibr" rid="B3">3</xref>]. Wnt signaling is one of the central cellular pathways commonly disrupted in several tumor types, including breast cancer [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Unlike colorectal cancer, evidence for genetic alterations of Wnt pathway components in breast cancer, such as adenomatous polyposis coli (<italic>APC</italic>) mutations, is rare [<xref ref-type="bibr" rid="B6">6</xref>]. Several lines of evidence suggest that in breast cancer the Wnt signaling pathway is disrupted predominantly through epigenetic aberrations, most of all by promoter methylation of genes encoding secreted Wnt inhibitory molecules. For instance, genes encoding secreted frizzled-related proteins (SFRP) and Wnt-inhibitory factor-1 (<italic>WIF1</italic>) were previously reported as frequent targets of epigenetic inactivation in breast cancer [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. In addition to this, we have recently shown that the putative Wnt signaling inhibitor Dickkopf-3 (<italic>DKK3</italic>) is functionally inactivated by promoter methylation in more than 60% of tumors from patients with invasive breast cancer [<xref ref-type="bibr" rid="B13">13</xref>]. Besides secreted inhibitors, two studies also reported frequent methylation of the <italic>APC </italic>gene in breast carcinomas [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Altogether, this provides strong evidence for an epigenetically disrupted and thereby activated Wnt signaling pathway in the development of human breast cancer.</p><p>There is increasing evidence that promoter methylation of cancer-related genes can be one of the most prevalent molecular markers for human cancer diseases [<xref ref-type="bibr" rid="B16">16</xref>]. The potential clinical applications of DNA-methylation biomarkers may include diagnosis of neoplasm, tumor classification, prediction of response to treatment, or patient prognosis [<xref ref-type="bibr" rid="B17">17</xref>]. Methylation of particular Wnt pathway genes has already been described as a potential biomarker for unfavorable patient outcome in human cancer. For instance, we have recently shown that methylation of <italic>SFRP1 </italic>as well as <italic>SFRP5 </italic>is associated with reduced patient overall survival in breast cancer [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. In contrast to this, high-frequent methylation of <italic>SFRP2 </italic>was not prognostically relevant in breast cancer [<xref ref-type="bibr" rid="B9">9</xref>], but was shown to comprise a diagnostic value as a sensitive screening marker for the stool-based detection of colorectal cancer and premalignant colorectal lesions [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. <italic>DKK3 </italic>methylation is associated with reduced DFS in acute lymphoblastic leukemia [<xref ref-type="bibr" rid="B21">21</xref>], and also with shorter OS in kidney cancer [<xref ref-type="bibr" rid="B22">22</xref>] and non-small cell lung cancer [<xref ref-type="bibr" rid="B23">23</xref>], as well as very recently reported with OS in gastric cancer [<xref ref-type="bibr" rid="B24">24</xref>]. Taken together, promoter methylation of Wnt signaling antagonists appears to provide a rich pool of novel tumor biomarkers in human cancer, potentially useful in the clinical setting by helping to improve management of this disease.</p><p>In the present study, we addressed the question to whether promoter methylation of two Wnt antagonist genes (<italic>WIF1 </italic>and <italic>DKK3</italic>), that were previously reported as hypermethylated in breast cancer, provides prognostically relevant information in this tumor entity. In univariate and multivariate analyses we have investigated gene methylation in a large cohort (n = 150) of invasive breast cancer specimens. We here demonstrate for the first time that <italic>DKK3 </italic>methylation, but not <italic>WIF1 </italic>methylation, is an independent prognostic factor indicating poor patient survival in human breast cancer.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patient material</title><p>Surgically resected samples were obtained from 150 unselected breast cancer patients at the Departments of Gynecology at the University Hospitals of Aachen, Jena, Regensburg and D&#x000fc;sseldorf in Germany from 1991 to 2005. For 19 patients, normal breast tissues were available. In all cases, at least two-board certified pathologists agreed on the diagnosis on breast cancer. The samples were recruited in a non-selective, consecutive manner. Cases were not stratified for any known pre-operative or pathological prognostic factor. Inclusion criteria for the study were: Female patients presenting with unilateral, primary invasive breast cancer without individual breast cancer history. Exclusion criteria were: neo-adjuvant chemotherapy prior to surgery, presentation with secondary breast cancer, or peritumorous carcinoma <italic>in situ </italic>present in the tumor sample. All patients gave informed consent for retention and analysis of their tissue for research purposes and the Institutional Review Boards of the participating centers approved the study. Tumor histology was determined according to the criteria of the WHO (2003), while disease stage was assessed according to UICC [<xref ref-type="bibr" rid="B25">25</xref>]. Histological, tumors were graded according to Bloom and Richardson, as modified by Elston and Ellis [<xref ref-type="bibr" rid="B26">26</xref>]. Hormone receptor status was assessed according to the scoring system developed by Remmele and Stegner [<xref ref-type="bibr" rid="B27">27</xref>]. For 125 patients follow-up data were available with a median time of 64 months (range 1 to 174 months). Patient characteristics of this cohort have been previously described [<xref ref-type="bibr" rid="B13">13</xref>].</p></sec><sec><title>Extraction of genomic DNA</title><p>Tumor material was snap-frozen in liquid nitrogen immediately after surgery. Hematoxylin/Eosin-stained sections were prepared for assessing the percentage of tumor cells; only samples with &#x0003e; 70% tumor cells were selected. A total of 20 tissue sections (20 &#x003bc;m each) per specimen was dissected in a cryotom and pooled. Normal breast tissue specimens were prepared likewise. For normal breast samples, the epithelial cell amount had to exceed 30% in order to be selected for further preparation. Samples were dissolved in lysis buffer followed by DNA isolation, using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. The extracted genomic DNA was finally diluted in 55 &#x003bc;l of Tris buffer (10 mM; pH 7.6).</p></sec><sec><title><italic>In silico </italic>promoter analysis</title><p>The <italic>WIF1 </italic>promoter, located at chromosome position 12q14.2, was investigated according to the contig ENSG00000156076 contained in the Ensembl database [<xref ref-type="bibr" rid="B28">28</xref>]. A genomic nucleotide sequence consisting of 1000 bp upstream of the annotated transcription start site (TSS) and 293 bp downstream of the TSS (first exon) was analyzed by methprimer software [<xref ref-type="bibr" rid="B29">29</xref>]. Criteria for CpG island prediction were adjusted to the definition from Takai and Jones [<xref ref-type="bibr" rid="B30">30</xref>], and included an observed/expected CpG ratio of &#x02265; 0.7 and a GC content of &#x02265; 60%. The identified CpG island proximal to the TSS was chosen for promoter methylation analysis. Methylation-specific PCR (MSP) primers were derived from a particular region within this island, which has been analyzed for CpG methylation by bisulfite genomic sequencing (BGS) in a previous study [<xref ref-type="bibr" rid="B11">11</xref>]. The <italic>DKK3 </italic>promoter, located at chromosome position 11p15.3, was investigated according to the contig ENSG00000050165 contained in the Ensembl database. A genomic nucleotide sequence consisting of 1000 bp upstream of the annotated TSS and 1001 bp downstream of the TSS was analyzed by methprimer software. The downstream region covered the first three exons of the gene, since <italic>DKK3 </italic>was reported to be alternatively transcribed under the control of two distinct promoters [<xref ref-type="bibr" rid="B31">31</xref>]. Methprimer software identified the existence of two distinct CpG islands, located proximal to either of the two predicted transcription start sites. The downstream CpG island was chosen for promoter methylation analysis, since the shorter <italic>DKK3 </italic>transcript was shown to be more commonly distributed in normal human tissues [<xref ref-type="bibr" rid="B31">31</xref>].</p></sec><sec><title>Bisulfite-modification and methylation-specific PCR</title><p>Approximately 1 &#x003bc;g of genomic DNA was bisulfite-modified using the EZ DNA Methylation Kit (Zymo Research, Orange, CA) according to the manufacturer's recommendations. The bisulfite-converted DNA was finally eluted in 20 &#x003bc;l of Tris buffer (10 mM; pH 7.6). Methylation-specific PCR was performed according to Herman <italic>et al</italic>. [<xref ref-type="bibr" rid="B32">32</xref>]. In short, 1 &#x003bc;l of modified DNA (~50 ng) was amplified using MSP primers (see Table <xref ref-type="table" rid="T1">1</xref>) that specifically recognized either the unmethylated or methylated promoter sequences after bisulfite conversion [<xref ref-type="bibr" rid="B32">32</xref>]. Reaction volumes of 25 &#x003bc;l contained 1 &#x000d7; MSP-buffer [<xref ref-type="bibr" rid="B33">33</xref>], 400 nM of each primer, and 1.25 mM of each dNTP. One drop of mineral oil was added to each reaction tube. The PCR was initiated as "Hot Start" PCR at 95&#x000b0;C and held at 80&#x000b0;C before the addition of 1.25 units <italic>Taq </italic>DNA polymerase (Promega, Madison, WI). Cycle conditions were: 95&#x000b0;C for 5 min, 34 cycles of 95&#x000b0;C for 30 sec, 55&#x000b0;C (58&#x000b0;C) for 30 sec, 72&#x000b0;C for 40 sec and a final extension at 72&#x000b0;C for 5 min. Amplification products were visualized on 3% low range ultra agarose gel (Bio-Rad Laboratories, Hercules, CA) containing ethidium bromide and illuminated under ultraviolet light. Specificity of MSP primers in detecting the promoter methylation status were demonstrated by use of universal unmethylated and universal poly-methylated DNA as template (Epi Tect Control DNA Set; Qiagen, Hilden, Germany). Sensitivity of the utilized primers and cycling conditions was defined by use of a dilution series in MSP assays, constituted of methylated DNA diluted with unmethylated DNA (50%, 10%, 1%, 0.1%, 0.01% and 0% methylation).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Oligonucleotide primers used in the study</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>Sequence (5' &#x02192; 3')</bold></td><td align="center"><bold>T<sub>A</sub></bold><break/><bold>[&#x000b0;C]</bold></td><td align="center"><bold>Primer</bold><break/><bold>[nM]</bold></td><td align="center"><bold>Product size (bp)</bold></td></tr></thead><tbody><tr><td align="left" colspan="5"><bold><italic>Methylation-specific PCR</italic></bold></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><italic>WIF1 </italic>unmethylated</td><td align="left">Forward: GGGTGTTTTATTGGGTGTATTGT</td><td align="center">55</td><td align="center">400</td><td align="center">154</td></tr><tr><td></td><td align="left">Reverse: AAAAAAACTAACACAAACAAAATACAAAC</td><td></td><td></td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><italic>WIF1 </italic>methylated</td><td align="left">Forward: CGTTTTATTGGGCGTATCGT</td><td align="center">55</td><td align="center">400</td><td align="center">145</td></tr><tr><td></td><td align="left">Reverse: ACTAACGCGAACGAAATACGA</td><td></td><td></td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><italic>DKK3 </italic>unmethylated</td><td align="left">Forward: TTAGGGGTGGGTGGTGGGGT</td><td align="center">58</td><td align="center">320</td><td align="center">126</td></tr><tr><td></td><td align="left">Reverse: CTACATCTCCACTCTACACCCA</td><td></td><td></td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><italic>DKK3 </italic>methylated</td><td align="left">Forward: GGGCGGGCGGCGGGGC</td><td align="center">58</td><td align="center">320</td><td align="center">120</td></tr><tr><td></td><td align="left">Reverse: ACATCTCCGCTCTACGCCCG</td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>T<sub>A</sub>, annealing temperature.</p></table-wrap-foot></table-wrap></sec><sec><title>Statistical evaluations</title><p>Statistical analyses were completed using SPSS 14.0 (SPSS, Chicago, IL). Differences were considered significant when <italic>P</italic>-values were below 0.05. To study statistical associations between clinicopathological factors and methylation status contingency tables and two-sided Fisher's exact test were accomplished. In case of multiple statistical tests, the false discovery rate controlling procedure was applied. Survival curves were calculated using the Kaplan-Meier method, with significance evaluated by two-sided log-rank statistics. OS (n = 125) was measured from the day of surgery until breast cancer-related death (n = 21) and was censored for patients alive at last contact (n = 91), in case of death unrelated to the tumor (n = 5) or when the death cause was unknown (n = 8). DFS (n = 125) was measured from surgery until local or distant relapse (n = 30) and was censored for patients alive without evidence of relapse at the last follow-up (n = 95). A stepwise multivariate Cox regression model was adjusted, testing the independent prognostic relevance of clinical/investigational factors. The limit for reverse selection procedures was p = 0.1. Only patients for whom the status of all variables was known (n = 103) were included in the proportional hazard models. The proportionality assumption for all variables was assessed with log-negative-log survival distribution functions. The variables tumor size (pT), node status (pN) and histological grade (G) were dichotomised into less and more progressive groups (pT1-2 <italic>vs</italic>. pT3-4; pN0 <italic>vs</italic>. pN1-3; G1-2 <italic>vs</italic>. G3).</p></sec></sec><sec><title>Results</title><sec><title><italic>WIF1 </italic>promoter methylation in primary breast carcinomas</title><p><italic>WIF1 </italic>promoter methylation in human breast cancer has been previously reported by Ai <italic>et al</italic>. [<xref ref-type="bibr" rid="B11">11</xref>], who demonstrated, by use of MSP, <italic>WIF1 </italic>methylation in 16 of 24 (67%) breast carcinoma samples. For three breast tumor specimens, these MSP results had also been confirmed by BGS. Unfortunately, in their study the <italic>WIF1 </italic>promoter regions investigated by MSP and BGS were not matching or overlapping, so we decided to analyze <italic>WIF1 </italic>promoter methylation in breast cancer by MSP in the particular promoter region that has been covered by BGS in the other study (Figure <xref ref-type="fig" rid="F1">1A</xref>). Initially, a dilution series of methylated DNA in an excess of unmethylated DNA (Epi Tect Control DNA, bisulfite-converted) was tested by MSP. This experiment determined the sensitivity of the utilized <italic>WIF1 </italic>MSP assay to be 1.0% in the detection of methylated DNA molecules (~0.1 ng) in a background of unmethylated DNA (~9.9 ng) (Figure <xref ref-type="fig" rid="F1">1B</xref>). Next, <italic>WIF1 </italic>promoter methylation was determined by MSP in 150 primary breast carcinoma specimens and also in 19 matching normal breast tissues. In all normal breast tissues, only unmethylated <italic>WIF1 </italic>promoter sequence could be detected, as indicated by exclusive amplification with primers recognizing the unmethylated DNA sequence (Figure <xref ref-type="fig" rid="F2">2</xref>). In contrast, 95 of 150 primary breast carcinomas (63.3%) revealed a methylated <italic>WIF1 </italic>promoter sequence, as indicated by amplification with primers specific to methylated DNA (Figure <xref ref-type="fig" rid="F2">2</xref>). The remaining 55 tumor specimens (36.7%) revealed solely unmethylated <italic>WIF1 </italic>promoter sequence. In general, tumor samples, despite methylation, also revealed unmethylated <italic>WIF1 </italic>promoter sequence, which is likely due to small contaminations with stromal and endothelial cells, as has also been previously described [<xref ref-type="bibr" rid="B34">34</xref>].</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Methylation analysis of the human <italic>WIF1 </italic>promoter</bold>. (<bold>A</bold>) A 1.29 kb genomic sequence of the <italic>WIF1 </italic>promoter, analyzed by methprimer software [<xref ref-type="bibr" rid="B29">29</xref>], revealed the presence of a CpG island (blue) between relative position 604 and 1153. Position 1000 indicates the transcription start site (TSS, arrow). A region of high CpG (red vertical bars) densitiy was chosen for MSP analysis. The black bar indicates the MSP amplicon. (<bold>B</bold>) Sensitivity of the utilized MSP primers was determined by a dilution series of methylated DNA with unmethylated DNA (Epi Tect control DNA, Qiagen). At least 1% of methylated DNA (~0.1 ng) can be detected with the <italic>WIF1 </italic>MSP primers. bp, base pair marker; NTC, 'no template control'.</p></caption><graphic xlink:href="1471-2407-9-217-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold><italic>WIF1 </italic>methylation in primary breast cancer</bold>. <italic>WIF1 </italic>methylation analyses of primary breast cancer specimens. MSP was performed on bisulfite-treated DNA from breast cancer (T) and matching normal primary breast tissues (N). MSP results from three representative matched pairs and eight additional breast carcinomas (#) are shown. DNA bands in lanes labeled with U indicate MSP products amplified with primers recognizing the unmethylated promoter sequence. DNA bands in lanes labeled with M represent amplified MSP products with methylation-specific primers. Peripheral blood lymphocytes (PBL) and breast cancer cell line ZR75-1 served as positive controls for the methylation-specific reaction, respectively. Water was used as template in the 'no template control' (NTC). Note that tumor tissue usually displayed a PCR product in the U-reaction as well, due to contaminating normal tissue (stromal cells, endothelial cells) present in the tumor specimens as has also been described by Suzuki <italic>et al</italic>. [<xref ref-type="bibr" rid="B34">34</xref>].</p></caption><graphic xlink:href="1471-2407-9-217-2"/></fig></sec><sec><title><italic>DKK3 </italic>promoter methylation in primary breast carcinomas</title><p>We have recently reported of frequent <italic>DKK3 </italic>promoter methylation in human breast cancer [<xref ref-type="bibr" rid="B13">13</xref>]. In the respective report, we have demonstrated that <italic>DKK3 </italic>methylation was present in 61.3% of breast cancer patients (92 of 150), whereas in 19 matching normal breast tissues only one sample (5.3%) revealed faint methylation signals. Ideally, the samples analyzed for <italic>WIF1 </italic>methylation in the present report were physically identical with the samples previously analyzed for <italic>DKK3 </italic>methylation. The previously analyzed <italic>DKK3 </italic>promoter region is pictured in Figure <xref ref-type="fig" rid="F3">3A</xref>. To allow a direct comparison between methylation of these two genes, we first assayed a dilution series of methylated DNA with unmethylated DNA by MSP using <italic>DKK3 </italic>methylation-specific primers (see above). This experiment determined the sensitivity of the utilized <italic>DKK3 </italic>MSP assay to be 1.0% in the detection of methylated DNA molecules (~0.1 ng) in a background of unmethylated DNA (~9.9 ng) (Figure <xref ref-type="fig" rid="F3">3B</xref>), thus enabling a subsequent correlation analysis in breast cancer employing the methylation results from both genes.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Methylation analysis of the human <italic>DKK3 </italic>promoter</bold>. (<bold>A</bold>) A 2.0 kb genomic sequence of the <italic>DKK3 </italic>promoter, analyzed by methprimer software [<xref ref-type="bibr" rid="B29">29</xref>], revealed the presence of two CpG islands (blue); one between relative position 834 and 1261 and another one between position 1529 and 1917. Two alternative tissue-specific <italic>DKK3 </italic>transcripts have been described [<xref ref-type="bibr" rid="B30">30</xref>]. Since transcription of the shorter transcript is widely distributed in normal tissues, we chose the region of the second transcription start site (TSS, arrow) for methylation analysis. Position 1000 indicates the alternative transcription start site of the longer transcript (TSS*, arrow). A region of high CpG (red vertical bars) densitiy within the second CpG island was chosen for MSP analysis. (<bold>B</bold>) Sensitivity of the utilized MSP primers was determined by a dilution series of methylated DNA with unmethylated DNA (Epi Tect control DNA, Qiagen). At least 1% of methylated DNA (~0.1 ng) can be detected with the <italic>DKK3 </italic>MSP primers. bp, base pair marker; NTC, 'no template control'.</p></caption><graphic xlink:href="1471-2407-9-217-3"/></fig></sec><sec><title>Association of <italic>WIF1 </italic>and <italic>DKK3 </italic>promoter methylation with clinicopathological parameters</title><p>For descriptive data analysis clinicopathological parameters were correlated with the <italic>WIF1 </italic>and <italic>DKK3 </italic>promoter methylation status. In a bivariate analysis, <italic>WIF1 </italic>methylation was not associated with patient age at diagnosis, tumor size, lymph node status, histological grade, histological type, and estrogen or progesterone receptor status (Table <xref ref-type="table" rid="T2">2</xref>). <italic>DKK3 </italic>methylation was associated with advanced patient age at diagnosis (p = 0.007), but not associated with any other of the investigated parameters (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Demographic/clinicopathological parameters in relation to <italic>WIF1 </italic>and <italic>DKK3 </italic>promoter methylation</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center" colspan="4"><bold><italic>WIF1 </italic>methylation</bold></td><td align="center" colspan="4"><bold><italic>DKK3 </italic>methylation</bold></td></tr><tr><td></td><td></td><td colspan="8"><hr></hr></td></tr><tr><td align="left"><bold>Variable</bold></td><td align="left"><bold>Categorization</bold></td><td align="center"><bold>n<sup>1</sup></bold></td><td align="center"><bold>No (%)</bold></td><td align="center"><bold>Yes (%)</bold></td><td align="center"><bold><italic>P</italic><sup>2</sup></bold></td><td align="center"><bold>n<sup>1</sup></bold></td><td align="center"><bold>No (%)</bold></td><td align="center"><bold>Yes (%)</bold></td><td align="center"><bold><italic>P</italic><sup>2</sup></bold></td></tr></thead><tbody><tr><td align="left" colspan="10"><bold><italic>Clinicopathological factors</italic></bold></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left" colspan="10">Age at diagnosis</td></tr><tr><td></td><td align="left">&#x0003c;57 years</td><td align="center">74</td><td align="center">32 (43)</td><td align="center">42 (57)</td><td align="center">0.127</td><td align="center">74</td><td align="center">37 (50)</td><td align="center">37 (50)</td><td align="center">0.007</td></tr><tr><td></td><td align="left">&#x02265; 57 years</td><td align="center">76</td><td align="center">23 (30)</td><td align="center">53 (70)</td><td></td><td align="center">76</td><td align="center">21 (28)</td><td align="center">55 (72)</td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left" colspan="10">Tumor size<sup>3</sup></td></tr><tr><td></td><td align="left">pT1-pT2</td><td align="center">129</td><td align="center">48 (37)</td><td align="center">81 (63)</td><td align="center">1.000</td><td align="center">129</td><td align="center">52 (40)</td><td align="center">77 (60)</td><td align="center">0.440</td></tr><tr><td></td><td align="left">pT3-pT4</td><td align="center">18</td><td align="center">7 (39)</td><td align="center">11 (61)</td><td></td><td align="center">18</td><td align="center">5 (28)</td><td align="center">13 (72)</td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left" colspan="10">Lymph node status<sup>3</sup></td></tr><tr><td></td><td align="left">pN0</td><td align="center">72</td><td align="center">29 (40)</td><td align="center">43 (60)</td><td align="center">0.606</td><td align="center">72</td><td align="center">32 (44)</td><td align="center">40 (56)</td><td align="center">0.170</td></tr><tr><td></td><td align="left">pN1-pN3</td><td align="center">71</td><td align="center">25 (35)</td><td align="center">46 (65)</td><td></td><td align="center">71</td><td align="center">23 (32)</td><td align="center">48 (67)</td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left" colspan="10">Histological grade</td></tr><tr><td></td><td align="left">G1-G2</td><td align="center">88</td><td align="center">28 (32)</td><td align="center">60 (68)</td><td align="center">0.170</td><td align="center">88</td><td align="center">31 (35)</td><td align="center">57 (65)</td><td align="center">0.313</td></tr><tr><td></td><td align="left">G3</td><td align="center">62</td><td align="center">27 (44)</td><td align="center">35 (57)</td><td></td><td align="center">62</td><td align="center">27 (44)</td><td align="center">35 (57)</td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left" colspan="10">Histological type</td></tr><tr><td></td><td align="left">IDC</td><td align="center">122</td><td align="center">43 (35)</td><td align="center">79 (65)</td><td></td><td align="center">122</td><td align="center">45 (37)</td><td align="center">77 (63)</td><td></td></tr><tr><td></td><td align="left">lobular</td><td align="center">19</td><td align="center">7 (37)</td><td align="center">12 (63)</td><td align="center">0.296</td><td align="center">19</td><td align="center">7 (37)</td><td align="center">12 (63)</td><td align="center">0.236</td></tr><tr><td></td><td align="left">other</td><td align="center">9</td><td align="center">5 (56)</td><td align="center">4 (44)</td><td></td><td align="center">9</td><td align="center">6 (67)</td><td align="center">3 (33)</td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left" colspan="10"><italic>Immunohistochemistry</italic></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left">Estrogen receptor</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="left">negative (IRS<sup>4 </sup>0&#x02013;2)</td><td align="center">47</td><td align="center">21 (45)</td><td align="center">26 (55)</td><td align="center">0.142</td><td align="center">47</td><td align="center">20 (43)</td><td align="center">27 (57)</td><td align="center">0.467</td></tr><tr><td></td><td align="left">positive (IRS 3&#x02013;12)</td><td align="center">98</td><td align="center">31 (32)</td><td align="center">67 (68)</td><td></td><td align="center">98</td><td align="center">35 (36)</td><td align="center">63 (64)</td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left" colspan="10">Progesterone receptor</td></tr><tr><td></td><td align="left">negative (IRS<sup>4 </sup>0&#x02013;2)</td><td align="center">51</td><td align="center">22 (43)</td><td align="center">29 (57)</td><td align="center">0.206</td><td align="center">51</td><td align="center">21 (41)</td><td align="center">30 (59)</td><td align="center">0.593</td></tr><tr><td></td><td align="left">positive (IRS 3&#x02013;12)</td><td align="center">94</td><td align="center">30 (32)</td><td align="center">64 (68)</td><td></td><td align="center">94</td><td align="center">34 (36)</td><td align="center">60 (64)</td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left" colspan="10"><italic>WIF1 promoter</italic></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">unmethylated</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td align="center">55</td><td align="center">29 (53)</td><td align="center">26 (47)</td><td align="center">0.009</td></tr><tr><td></td><td align="left">methylated</td><td align="center">-</td><td align="center">-</td><td align="center">-</td><td></td><td align="center">95</td><td align="center">29 (31)</td><td align="center">66 (69)</td><td></td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>Only female patients with primary, unilateral invasive breast cancer were included. <sup>2</sup>Fisher's exact test. <sup>3</sup>According to UICC: TNM Classification of Malignant Tumours [<xref ref-type="bibr" rid="B25">25</xref>]. <sup>4</sup>IRS, immunoreactivity score according to Remmele and Stegner [<xref ref-type="bibr" rid="B27">27</xref>]. Percentages may not sum to 100 due to rounding. IDC, invasive ductal carcinoma; n.a., not available.</p></table-wrap-foot></table-wrap></sec><sec><title>Correlation of <italic>WIF1 </italic>and <italic>DKK3 </italic>promoter methylation in primary breast carcinoma</title><p>In a bivariate analysis, methylation of the <italic>WIF1 </italic>promoter was significantly associated with methylation of the <italic>DKK3 </italic>promoter (p = 0.009) (Table <xref ref-type="table" rid="T2">2</xref>). Both gene promoters were mutually unmethylated in tumors from 29 of 150 patients (19.3%) and mutually methylated in tumors from 66 of 150 patients (44.0%) (Figure <xref ref-type="fig" rid="F4">4</xref>). For 55 of 150 patients (36.7%) the methylation status of the <italic>WIF1 </italic>and <italic>DKK3 </italic>promoter differed: <italic>WIF1 </italic>methylation together with <italic>DKK3 </italic>non-methylation was detected in 29/250 patients (19.3%), whereas <italic>WIF1 </italic>non-methylation together with <italic>DKK3 </italic>methylation was detected in 26 of 150 patients (17.3%).</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Distribution of <italic>WIF1 </italic>and <italic>DKK3 </italic>promoter methylation in primary breast carcinomas</bold>. Methylation status of either gene has been determined by MSP in the same tumors. Of n = 150 breast cancer patients, the larger fraction reveals an identical methylation status of both genes (63.3%). In the remaining smaller fraction (36.6%), methylation of only one of the two genes could be detected. In total, <italic>WIF1 </italic>methylation was significantly associated with <italic>DKK3 </italic>methylation (p = 0.009; Fisher's exact test).</p></caption><graphic xlink:href="1471-2407-9-217-4"/></fig></sec><sec><title>Association of <italic>WIF1 </italic>promoter methylation with patient survival</title><p>Patient OS and DFS were compared between methylated <italic>versus </italic>unmethylated <italic>WIF1 </italic>promoter sequence by univariate Kaplan-Meier analysis using log-rank statistics. In this analysis, <italic>WIF1 </italic>methylation was not significantly associated with patient OS (p = 0.656) or patient DFS (p = 0.154) (Table <xref ref-type="table" rid="T3">3</xref>), as also demonstrated by Kaplan-Meier survival curves (Figure <xref ref-type="fig" rid="F5">5</xref>). As expected, a positive lymph node status (pN1-3) and higher histological grade (G3) were found to be associated with decreased OS (p = 0.002; p = 0.001) and DFS (p &#x0003c; 0.001; p = 0.012).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Univariate survival analysis of clinicopathological and molecular factors (log-rank test)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Variable</bold></td><td align="left"><bold>Categorization</bold></td><td align="center" colspan="3"><bold>Overall survival</bold></td><td align="center" colspan="3"><bold>Disease-free survival</bold></td></tr><tr><td></td><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td></td><td align="center"><bold>n<sup>1</sup></bold></td><td align="center"><bold>events</bold></td><td align="center"><bold><italic>P</italic><sup>2</sup></bold></td><td align="center"><bold>n<sup>1</sup></bold></td><td align="center"><bold>events</bold></td><td align="center"><bold><italic>P</italic><sup>2</sup></bold></td></tr></thead><tbody><tr><td align="left" colspan="8"><bold><italic>Clinicopathological factors</italic></bold></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left" colspan="8">Age at diagnosis</td></tr><tr><td></td><td align="left">&#x0003c;57 years</td><td align="center">64</td><td align="center">7</td><td align="center">0.094</td><td align="center">64</td><td align="center">16</td><td align="center">0.711</td></tr><tr><td></td><td align="left">&#x02265; 57 years</td><td align="center">61</td><td align="center">14</td><td></td><td align="center">61</td><td align="center">14</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left" colspan="8">Tumor size<sup>3</sup></td></tr><tr><td></td><td align="left">pT1-pT2</td><td align="center">107</td><td align="center">17</td><td align="center">0.372</td><td align="center">107</td><td align="center">25</td><td align="center">0.427</td></tr><tr><td></td><td align="left">pT3-pT4</td><td align="center">16</td><td align="center">4</td><td></td><td align="center">16</td><td align="center">5</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left" colspan="8">Lymph node status<sup>3</sup></td></tr><tr><td></td><td align="left">pN0</td><td align="center">54</td><td align="center">3</td><td align="center">0.002</td><td align="center">54</td><td align="center">5</td><td align="center">&#x0003c;0.001</td></tr><tr><td></td><td align="left">pN1-pN3</td><td align="center">65</td><td align="center">18</td><td></td><td align="center">65</td><td align="center">24</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left" colspan="8">Histological grade</td></tr><tr><td></td><td align="left">G1-G2</td><td align="center">72</td><td align="center">5</td><td align="center">0.001</td><td align="center">72</td><td align="center">11</td><td align="center">0.012</td></tr><tr><td></td><td align="left">G3</td><td align="center">53</td><td align="center">16</td><td></td><td align="center">53</td><td align="center">19</td><td></td></tr><tr><td align="left" colspan="8">Histological type</td></tr><tr><td></td><td align="left">IDC</td><td align="center">101</td><td align="center">19</td><td align="center">0.267</td><td align="center">101</td><td align="center">22</td><td align="center">0.277</td></tr><tr><td></td><td align="left">other</td><td align="center">24</td><td align="center">2</td><td></td><td align="center">24</td><td align="center">8</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left" colspan="8"><italic>Immunohistochemistry</italic></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left" colspan="8">Estrogen receptor</td></tr><tr><td></td><td align="left">negative (IRS<sup>4 </sup>0&#x02013;2)</td><td align="center">40</td><td align="center">9</td><td align="center">0.155</td><td align="center">40</td><td align="center">9</td><td align="center">0.962</td></tr><tr><td></td><td align="left">positive (IRS 3&#x02013;12)</td><td align="center">80</td><td align="center">12</td><td></td><td align="center">80</td><td align="center">21</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left" colspan="8">Progesterone receptor</td></tr><tr><td></td><td align="left">negative (IRS<sup>4 </sup>0&#x02013;2)</td><td align="center">39</td><td align="center">9</td><td align="center">0.154</td><td align="center">39</td><td align="center">13</td><td align="center">0.087</td></tr><tr><td></td><td align="left">positive (IRS 3&#x02013;12)</td><td align="center">81</td><td align="center">12</td><td></td><td align="center">81</td><td align="center">17</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left" colspan="8"><italic>WIF1 promoter</italic></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">unmethylated</td><td align="center">47</td><td align="center">9</td><td align="center">0.656</td><td align="center">47</td><td align="center">8</td><td align="center">0.154</td></tr><tr><td></td><td align="left">methylated</td><td align="center">78</td><td align="center">12</td><td></td><td align="center">78</td><td align="center">22</td><td></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td align="left" colspan="8"><italic>DKK3 promoter</italic></td></tr><tr><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">unmethylated</td><td align="center">46</td><td align="center">1</td><td align="center">&#x0003c;0.001</td><td align="center">46</td><td align="center">7</td><td align="center">0.037</td></tr><tr><td></td><td align="left">methylated</td><td align="center">79</td><td align="center">20</td><td></td><td align="center">79</td><td align="center">23</td><td></td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>Only female patients with primary, unilateral invasive breast cancer were included. <sup>2</sup>Log-rank test. <sup>3</sup>According to UICC: TNM Classification of Malignant Tumours [<xref ref-type="bibr" rid="B25">25</xref>]. <sup>4</sup>IRS, immunoreactivity score according to Remmele and Stegner [<xref ref-type="bibr" rid="B27">27</xref>]. IDC, invasive ductal carcinoma.</p></table-wrap-foot></table-wrap><fig position="float" id="F5"><label>Figure 5</label><caption><p><bold>Univariate Kaplan-Meier survival analysis of breast cancer patients in relation to <italic>WIF1 </italic>and <italic>DKK3 </italic>promoter methylation</bold>. (<bold>A</bold>) Overall survival and (<bold>B</bold>) disease-free survival are not associated with <italic>WIF1 </italic>promoter methylation in human breast cancer. Solid lines indicate methylated <italic>WIF1 </italic>promoter; dotted lines indicate unmethylated <italic>WIF1 </italic>promoter in the tumor. (<bold>C</bold>) In contrast, methylation of the <italic>DKK3 </italic>promoter in tumor tissue (solid line) is significantly associated with adverse patient overall survival, whereas patients with an unmethylated <italic>DKK3 </italic>promoter in the tumor tissue have a very favorable clinical outcome (dotted line) (p &#x0003c; 0.001). (<bold>D</bold>) In addition, <italic>DKK3</italic>-methylated tumors reveal a significant shorter time to recurrence (solid line), as compared to tumors harboring an unmethylated <italic>DKK3 </italic>promoter (dotted line) (p = 0.037). Vertical tick marks represent censored patients.</p></caption><graphic xlink:href="1471-2407-9-217-5"/></fig></sec><sec><title>Association of <italic>DKK3 </italic>promoter methylation with patient survival</title><p>Patient OS and DFS were compared between methylated <italic>versus </italic>unmethylated <italic>DKK3 </italic>promoter sequence. In contrast to <italic>WIF1 </italic>methylation, <italic>DKK3 </italic>methylation was significantly associated with poor OS (5-year survival: 75% for cases with methylated alleles <italic>vs</italic>. 97% for cases with unmethylated alleles; 10-year survival: 54% <italic>vs</italic>. 97%; p = 0.0005; Table <xref ref-type="table" rid="T3">3</xref>) and shorter DFS (5-year survival: 67% for cases with methylated alleles <italic>vs</italic>. 84% for cases with unmethylated alleles; 10-year-survival: 58% <italic>vs</italic>. 78%; p = 0.037; Table <xref ref-type="table" rid="T3">3</xref>), as also illustrated by Kaplan-Meier survival curves (Figure <xref ref-type="fig" rid="F5">5</xref>). Based on a mean OS of 141 months (95% CI: 127&#x02013;154 months) patients without <italic>DKK3 </italic>methylation in the tumor tissue revealed much longer mean OS (170 months, 95% CI: 163&#x02013;177 months) than patients with <italic>DKK3 </italic>methylation in the tumor tissue (113 months, 95% CI: 95&#x02013;131 months). Based on a mean DFS of 99 months (95% CI: 90&#x02013;107 months) patients without <italic>DKK3 </italic>methylation in the tumor revealed longer mean DFS (110 months, 95% CI: 99&#x02013;122 months) than patients with <italic>DKK3 </italic>methylation in the tumor (86 months, 95% CI: 75&#x02013;97 months). Multivariate Cox regression models were calculated and adjusted to assess factor-related hazard risks and to test for independency of <italic>DKK3 </italic>methylation as a prognostic factor in patient OS and DFS. The strength of the association between <italic>DKK3 </italic>methylation and unfavourable patient outcome is presented in Table <xref ref-type="table" rid="T4">4</xref> and Table <xref ref-type="table" rid="T5">5</xref>. Multivariate, <italic>DKK3 </italic>methylation in breast carcinoma represented an independent and strong risk factor for OS (HR: 14.4; 95% CI: 1.9 &#x02013; 111.6; p = 0.011; Table <xref ref-type="table" rid="T4">4</xref>). In DFS the prognostic potency of <italic>DKK3 </italic>methylation was weaker than in OS (HR: 2.5; 95% CI: 1.0 &#x02013; 6.0; p = 0.047; Table <xref ref-type="table" rid="T5">5</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Multivariate Cox regression analysis of <italic>DKK3 </italic>promoter methylation with regard to overall survival</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td></td><td align="center" colspan="3"><bold>Multivariate analysis</bold><break/><bold>Overall survival</bold><break/><bold>(global model)</bold></td><td align="center" colspan="3"><bold>Multivariate analysis</bold><break/><bold>Overall survival</bold><break/><bold>(reverse selection procedure<sup>2</sup>)</bold></td></tr></thead><tbody><tr><td align="left" colspan="3"><bold>Variable</bold></td><td align="center"><bold>HR</bold></td><td align="center"><bold>95% CI<sup>1</sup></bold></td><td align="center"><bold><italic>P</italic></bold></td><td align="center"><bold>HR</bold></td><td align="center"><bold>95% CI<sup>1</sup></bold></td><td align="center"><bold><italic>P</italic></bold></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Age at diagnosis</td><td align="left">&#x0003c;57 years</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td align="center">1.0</td><td></td><td></td></tr><tr><td></td><td align="left">&#x02265; 57 years</td><td align="center">1</td><td align="center">1.78</td><td align="center">0.63 &#x02013; 4.99</td><td align="center">0.276</td><td align="center">2.27</td><td align="center">0.85 &#x02013; 6.07</td><td align="center">0.104</td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Tumor size</td><td align="left">pT1-2</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="left">pT3-4</td><td align="center">1</td><td align="center">0.83</td><td align="center">0.25 &#x02013; 2.78</td><td align="center">0.766</td><td></td><td></td><td></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Lymph nodes</td><td align="left">pN0</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td align="center">1.0</td><td></td><td></td></tr><tr><td></td><td align="left">pN1-3</td><td align="center">1</td><td align="center">5.47</td><td align="center">1.46 &#x02013; 20.53</td><td align="center">0.012</td><td align="center">4.50</td><td align="center">1.26 &#x02013; 15.87</td><td align="center">0.021</td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Histological grade</td><td align="left">G1</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td align="center">1.0</td><td></td><td></td></tr><tr><td></td><td align="left">G2-G3</td><td align="center">1</td><td align="center">4.36</td><td align="center">1.54 &#x02013; 12.40</td><td align="center">0.006</td><td align="center">4.50</td><td align="center">1.57 &#x02013; 12.87</td><td align="center">0.005</td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Histological type</td><td align="left">ductal</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="left">other</td><td align="center">1</td><td align="center">0.46</td><td align="center">0.09 &#x02013; 2.22</td><td align="center">0.330</td><td></td><td></td><td></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Estrogen receptor</td><td align="left">negative</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td align="center">1.0</td><td></td><td></td></tr><tr><td></td><td align="left">positive</td><td align="center">1</td><td align="center">0.51</td><td align="center">0.18 &#x02013; 1.47</td><td align="center">0.214</td><td align="center">0.43</td><td align="center">0.17 &#x02013; 1.09</td><td align="center">0.426</td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Progesterone receptor</td><td align="left">negative</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="left">positive</td><td align="center">1</td><td align="center">0.57</td><td align="center">0.21 &#x02013; 1.54</td><td align="center">0.270</td><td></td><td></td><td></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left"><italic>DKK3 </italic>promoter</td><td align="left">unmethylated</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td align="center">1.0</td><td></td><td></td></tr><tr><td></td><td align="left">methylated</td><td align="center">1</td><td align="center">14.41</td><td align="center">1.86 &#x02013; 111.56</td><td align="center">0.011</td><td align="center">13.68</td><td align="center">1.77&#x02013;105.52</td><td align="center">0.012</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>Confidence interval (CI) on the estimated hazard ratio (HR). <sup>2</sup>Only terms that remained in the model after reverse selection are listed. All variables were stratified binary according to Table 3.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Multivariate Cox regression analysis of <italic>DKK3 </italic>promoter methylation with regard to disease-free survival</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td></td><td align="center" colspan="3"><bold>Multivariate analysis</bold><break/><bold>Disease-free survival</bold><break/><bold>(global model)</bold></td><td align="center" colspan="3"><bold>Multivariate analysis</bold><break/><bold>Disease-free survival</bold><break/><bold>(reverse selection procedure<sup>2</sup>)</bold></td></tr></thead><tbody><tr><td align="left" colspan="3"><bold>Variable</bold></td><td align="center"><bold>HR</bold></td><td align="center"><bold>95% CI<sup>1</sup></bold></td><td align="center"><bold><italic>P</italic></bold></td><td align="center"><bold>HR</bold></td><td align="center"><bold>95% CI<sup>1</sup></bold></td><td align="center"><bold><italic>P</italic></bold></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Age at diagnosis</td><td align="left">&#x0003c;57 years</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="left">&#x02265; 57 years</td><td align="center">1</td><td align="center">0.57</td><td align="center">0.24 &#x02013; 1.33</td><td align="center">0.191</td><td></td><td></td><td></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Tumor size</td><td align="left">pT1-2</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="left">pT3-4</td><td align="center">1</td><td align="center">0.61</td><td align="center">0.22 &#x02013; 1.72</td><td align="center">0.353</td><td></td><td></td><td></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Lymph nodes</td><td align="left">pN0</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td align="center">1.0</td><td></td><td></td></tr><tr><td></td><td align="left">pN1-3</td><td align="center">1</td><td align="center">4.24</td><td align="center">1.50 &#x02013; 11.96</td><td align="center">0.006</td><td align="center">4.01</td><td align="center">1.49 &#x02013; 10.81</td><td align="center">0.006</td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Histological grade</td><td align="left">G1</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td align="center">1.0</td><td></td><td></td></tr><tr><td></td><td align="left">G2-G3</td><td align="center">1</td><td align="center">2.01</td><td align="center">0.91 &#x02013; 4.43</td><td align="center">0.086</td><td align="center">1.93</td><td align="center">0.88 &#x02013; 4.24</td><td align="center">0.102</td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Histological type</td><td align="left">IDC</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="left">other</td><td align="center">1</td><td align="center">1.04</td><td align="center">0.42&#x02013;2.62</td><td align="center">0.929</td><td></td><td></td><td></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Estrogen receptor</td><td align="left">negative</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="left">positive</td><td align="center">1</td><td align="center">2.17</td><td align="center">0.78 &#x02013; 6.03</td><td align="center">0.137</td><td></td><td></td><td></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">Progesterone receptor</td><td align="left">negative</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td align="center">1.0</td><td></td><td></td></tr><tr><td></td><td align="left">positive</td><td align="center">1</td><td align="center">0.36</td><td align="center">0.15 &#x02013; 0.88</td><td align="center">0.025</td><td align="center">0.53</td><td align="center">0.25 &#x02013; 1.11</td><td align="center">0.091</td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left"><italic>DKK3 </italic>promoter</td><td align="left">unmethylated</td><td align="center">0</td><td align="center">1.0</td><td></td><td></td><td align="center">1.0</td><td></td><td></td></tr><tr><td></td><td align="left">methylated</td><td align="center">1</td><td align="center">2.46</td><td align="center">1.01 &#x02013; 5.97</td><td align="center">0.047</td><td align="center">2.08</td><td align="center">0.88 &#x02013; 4.88</td><td align="center">0.094</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>Confidence interval (CI) on the estimated hazard ratio (HR). <sup>2</sup>Only terms that remained in the model after reverse selection are listed. All variables were stratified binary according to Table 3.</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>It was previously reported that expression of the Wnt antagonist genes <italic>WIF1 </italic>and <italic>DKK3 </italic>is downregulated in several tumor entities as a consequence of epigenetic DNA modification [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. WIF1 is a conserved Wnt-binding protein that prevents Wnt ligands from interacting with membranous frizzled receptors, thus may inhibit activation of the Wnt/&#x003b2;-catenin signaling cascade [<xref ref-type="bibr" rid="B37">37</xref>]. In breast, lung, prostate and bladder cancer, WIF1 expression was found to be frequently downregulated [<xref ref-type="bibr" rid="B38">38</xref>], suggesting it might represent a tumor suppressor gene. In breast cancer, this downregulation could be attributed to hypermethylation of the <italic>WIF1 </italic>promoter [<xref ref-type="bibr" rid="B11">11</xref>], as demonstrated both in breast cell lines and in primary breast carcinomas. In our study, methylation of the <italic>WIF1 </italic>promoter was detected in 63% of invasive tumors from breast cancer patients, thus being in good agreement with previous results from Ai <italic>et al</italic>. [<xref ref-type="bibr" rid="B11">11</xref>], who reported a frequency of 67% for <italic>WIF1 </italic>methylation in mammary tumors. Differences may arise through different sample sizes (n = 150 and n = 24) as well as different promoter locations assessed in either study. DKK3 is a further secreted inhibitor of Wnt signaling, but in contrast to WIF1 does not sequester Wnt ligands. The actual mechanism by which DKK3 acts inhibitory on Wnt pathway activation has not been identified yet, but suppression of DKK3 increased &#x003b2;-catenin/T-cell factor (TCF)-dependent gene activity in mammary cells [<xref ref-type="bibr" rid="B39">39</xref>], cancerous lung cells [<xref ref-type="bibr" rid="B40">40</xref>] and glioma [<xref ref-type="bibr" rid="B41">41</xref>]. Likewise to <italic>WIF1</italic>, the <italic>DKK3 </italic>gene was also reported as a frequent target of epigenetic inactivation in numerous tumor entities, <italic>e.g</italic>. in lung cancer, prostate cancer and leukemia [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B42">42</xref>], suggesting that DKK3 may exert tumor suppressive functions. In a recent report, we have demonstrated that <italic>DKK3 </italic>is frequently inactivated in invasive breast carcinomas by promoter methylation leading to loss of DKK3 expression [<xref ref-type="bibr" rid="B13">13</xref>]. This epimutation affected 92 of 150 investigated breast cancer patients (61%). Since these samples were identical to the samples for which we now have determined <italic>WIF1 </italic>methylation, we were able to perform a combined analysis of both genes' methylation in breast cancer.</p><p>In a bivariate analysis, <italic>WIF1 </italic>methylation status in breast carcinomas was significantly associated with the <italic>DKK3 </italic>methylation status. Despite, within the cohort of carcinomas being affected by methylation of either the <italic>DKK3 </italic>or <italic>WIF1 </italic>gene, a large fraction (45%) showed methylation in one gene only. This demonstrates that in spite of a statistical association between methylation of the two genes, there is still a large fraction of breast cancer patients with different <italic>DKK3/WIF1 </italic>methylation pattern. Therefore, it is unlikely that methylation of both Wnt antagonist genes is a mandatory mutual carcinogenic event. In a further correlation analysis, neither of the two genes was associated with relevant clinicopathological features, except for <italic>DKK3 </italic>methylation being associated with advanced patient age. Age-dependent promoter methylation has been reported previously [<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref>] and may randomly overlay the effects of gene-specific promoter methylation that can lead to the development of distinct cancer subtypes. The absence of an association between <italic>WIF1 </italic>or <italic>DKK3 </italic>methylation with important clinicopathological factors like tumor size, histological grade and lymph node invasion strongly suggests that methylation of either gene is an early carcinogenic event in breast cancer development, rather than contributing to tumor progression.</p><p>Most important, major differences between <italic>WIF1 </italic>and <italic>DKK3 </italic>methylation arise in their association with breast cancer patient survival. <italic>WIF1 </italic>methylation showed no significance in clinical patient outcome in contrast to <italic>DKK3 </italic>methylation, which was tightly associated with adverse patient OS and weaker with short DFS in our study. Patients harboring <italic>DKK3 </italic>methylation in the tumor had a poor prognosis (54% chance of 10-years OS) in contrast to patients retaining an unmethylated <italic>DKK3 </italic>promoter, who had a favorable prognosis (97% chance of 10-years OS). This finding was supported by a multivariate Cox regression analysis in which <italic>DKK3</italic>-methylated patients revealed a high risk of tumor-related death (HR: 14.4). Hence, this parameter outperformed classical prognostic factors in our patient cohort, <italic>i.e</italic>. high histological grade (HR: 4.4) or a positive lymph node status (HR: 5.5). Unproportional HRs of high impact were rarely achieved even in studies with very large sample size numbers, neither by strong conventional factors like node status (HR: 2.4) [<xref ref-type="bibr" rid="B45">45</xref>] and grade (HR: 5.7) [<xref ref-type="bibr" rid="B46">46</xref>] nor by investigational factors like the tissue urokinase-type plasminogen activator/inhibitor (uPA/PAI), which in case of high level exposes patients to a five times greater risk of dying from breast cancer [<xref ref-type="bibr" rid="B47">47</xref>]. In conclusion, our results demonstrate that determination of the <italic>DKK3 </italic>methylation status may provide valuable information to aid prognostication in the clinical management of breast cancer patients. Notably, methylation of the <italic>DKK3 </italic>promoter was recently shown to be prognosis relevant also in other tumor entities, such as in acute lymphoblastic leukemia, kidney cancer, lung cancer, and gastric cancer [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B24">24</xref>], pointing to a potential clinical use of this marker in several cancer diseases.</p><p>Our findings raise expectations towards translation of such methylation markers into clinical practice. As an example, <italic>DKK3 </italic>may be a prime candidate gene to be incorporated into diagnostic multimarker panels, for its aberrant methylation is specific to malignant cells in breast cancer [<xref ref-type="bibr" rid="B13">13</xref>]. Preliminary results from our laboratory revealed that <italic>DKK3 </italic>methylation can be detected with high clinical sensitivity and specificity in blood serum of breast cancer patients independent of tumor size and node status (unpublished data). The presence of detectable tumor DNA in serum is generally associated with poor prognosis [<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>], and taken together with its marker performance in solid breast tumor tissue, <italic>DKK3 </italic>methylation fulfils essential prerequisites as a biomarker in a blood-borne assay, of which we will report in a future study.</p><p>In summary, we here demonstrate that although <italic>WIF1 </italic>and <italic>DKK3 </italic>promoter methylation are similar frequent alterations in human breast cancer, only <italic>DKK3 </italic>methylation appears to be a survival risk factor for breast cancer patients and thus might be useful as prognostic marker in clinical oncology helping to improve patient outcome.</p></sec><sec><title>Conclusion</title><p>This study shows that the Wnt antagonist gene <italic>WIF1 </italic>is frequently inactivated by promoter hypermethylation in human breast cancer. Although <italic>WIF1 </italic>is similarly frequent hypermethylated like the Wnt antagonist gene <italic>DKK3</italic>, and neither gene methylation is associated with relevant clinicopathological factors, <italic>DKK3 </italic>methylation is an independent prognostic factor in breast cancer patient survival, whereas <italic>WIF1 </italic>methylation is not. These differences may reflect subtle distinctions in the biological roles of the two related molecules in inhibiting Wnt/&#x003b2;-catenin signaling.</p></sec><sec><title>Abbreviations</title><p>BGS: bisulfite genomic sequencing; BMBF: Bundesministerium f&#x000fc;r Bildung und Forschung; CI: confidence interval; DFS: disease-free survival; DKK3: Dickkopf-3; ER: estrogen receptor; HR: hazard ratio; MSP: methylation-specific polymerase chain reaction; NTC: no template control; OS: overall survival; PCP: planar cell polarity pathway; PCR: polymerase chain reaction; PR: progesterone receptor; TCF: T-cell factor; UICC: International Union Against Cancer; UMD: universal methylated DNA; UUD: universal unmethylated DNA; WHO: World Health Organization; WIF1: Wnt-inhibitory factor 1.</p></sec><sec><title>Competing interests</title><p>ED has declared that he has submitted a patent application on the use of <italic>DKK3 </italic>promoter methylation. The other authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>JV carried out the methylation experiments, contributed to statistical evaluations, participated in the conception and design of the study, and wrote the manuscript. PJW participated in statistical analyses and data interpretation, and critically revised the manuscript. TF and PJS supported with expertise in statistical analyses, and critically revised the manuscript. AH provided clinical samples and clinicopathological data, and critically revised the manuscript. RK participated in the design and coordination of the study, and critically revised the manuscript. ED planned and coordinated the study, and critically revised the manuscript. All authors have given final approval of the version to be published.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/9/217/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The expert technical assistance of Sevim Alkaya, Sonja von Ser&#x000e9;nyi and Inge Losen is greatly appreciated. We thank Dr. Dieter Niederacher (Heinrich-Heine University, D&#x000fc;sseldorf, Germany) and Prof. Matthias D&#x000fc;rst (Friedrich-Schiller University, Jena, Germany) for kindly providing patient samples as well as Dr. Monika Klinkhammer-Schalke and Dr. Felicitas Horn (Tumour Registry, Regensburg, Germany) for continuous help in obtaining clinical follow-up data. This work is a research project within the German Human Genome Project and has been supported by the BMBF grant 01KW0401 to ED.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Corn</surname><given-names>PG</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name></person-group><article-title>A gene hypermethylation profile of human cancer</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3225</fpage><lpage>3229</lpage><pub-id pub-id-type="pmid">11309270</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wildschwendter</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><article-title>DNA methylation and breast carcinogenesis</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>5462</fpage><lpage>5482</lpage><pub-id pub-id-type="pmid">12154408</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1205606</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulero-Navarro</surname><given-names>S</given-names></name><name><surname>Esteller</surname><given-names>M</given-names></name></person-group><article-title>Epigenetic biomarkers for human cancer: The time is now</article-title><source>Crit Rev Oncol Hematol</source><year>2008</year><volume>68</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">18430583</pub-id><pub-id pub-id-type="doi">10.1016/j.critrevonc.2008.03.001</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Howe</surname><given-names>LR</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name></person-group><article-title>Wnt signaling and breast cancer</article-title><source>Cancer Biol Ther</source><year>2004</year><volume>3</volume><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">14739782</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aguilera</surname><given-names>O</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>A</given-names></name><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Fraga</surname><given-names>MF</given-names></name></person-group><article-title>Epigenetic alterations of the Wnt/beta-catenin pathway in human disease</article-title><source>Endocr Metab Immune Disord Drug Targets</source><year>2007</year><volume>7</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">17346200</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furuuchi</surname><given-names>K</given-names></name><name><surname>Tada</surname><given-names>M</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Kataoka</surname><given-names>A</given-names></name><name><surname>Furuuchi</surname><given-names>N</given-names></name><name><surname>Hamada</surname><given-names>J</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Todo</surname><given-names>S</given-names></name><name><surname>Moriuchi</surname><given-names>T</given-names></name></person-group><article-title>Somatic mutations of the APC gene in primary breast cancers</article-title><source>Am J Pathol</source><year>2000</year><volume>156</volume><fpage>1997</fpage><lpage>2005</lpage><pub-id pub-id-type="pmid">10854222</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veeck</surname><given-names>J</given-names></name><name><surname>Niederacher</surname><given-names>D</given-names></name><name><surname>An</surname><given-names>H</given-names></name><name><surname>Klopocki</surname><given-names>E</given-names></name><name><surname>Wiesmann</surname><given-names>F</given-names></name><name><surname>Betz</surname><given-names>B</given-names></name><name><surname>Galm</surname><given-names>O</given-names></name><name><surname>Camara</surname><given-names>O</given-names></name><name><surname>D&#x000fc;rst</surname><given-names>M</given-names></name><name><surname>Kristiansen</surname><given-names>G</given-names></name><name><surname>Huszka</surname><given-names>C</given-names></name><name><surname>Kn&#x000fc;chel</surname><given-names>R</given-names></name><name><surname>Dahl</surname><given-names>E</given-names></name></person-group><article-title>Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis</article-title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>3479</fpage><lpage>3488</lpage><pub-id pub-id-type="pmid">16449975</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1209386</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>PK</given-names></name><name><surname>Mehrotra</surname><given-names>J</given-names></name><name><surname>D'Costa</surname><given-names>A</given-names></name><name><surname>Fackler</surname><given-names>MJ</given-names></name><name><surname>Garrett-Mayer</surname><given-names>E</given-names></name><name><surname>Argani</surname><given-names>P</given-names></name><name><surname>Sukumar</surname><given-names>S</given-names></name></person-group><article-title>Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer</article-title><source>Cancer Biol Ther</source><year>2006</year><volume>5</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">16410723</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veeck</surname><given-names>J</given-names></name><name><surname>Noetzel</surname><given-names>E</given-names></name><name><surname>Bektas</surname><given-names>N</given-names></name><name><surname>Jost</surname><given-names>E</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Kn&#x000fc;chel</surname><given-names>R</given-names></name><name><surname>Dahl</surname><given-names>E</given-names></name></person-group><article-title>Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer</article-title><source>Mol Cancer</source><year>2008</year><volume>7</volume><fpage>83</fpage><pub-id pub-id-type="pmid">18990230</pub-id><pub-id pub-id-type="doi">10.1186/1476-4598-7-83</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veeck</surname><given-names>J</given-names></name><name><surname>Geisler</surname><given-names>C</given-names></name><name><surname>Noetzel</surname><given-names>E</given-names></name><name><surname>Alkaya</surname><given-names>S</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Kn&#x000fc;chel</surname><given-names>R</given-names></name><name><surname>Dahl</surname><given-names>E</given-names></name></person-group><article-title>Epigenetic inactivation of the Secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>991</fpage><lpage>998</lpage><pub-id pub-id-type="pmid">18356147</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgn076</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ai</surname><given-names>L</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Fields</surname><given-names>CR</given-names></name><name><surname>Kim</surname><given-names>WJ</given-names></name><name><surname>Lee</surname><given-names>MW</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Brown</surname><given-names>KD</given-names></name><name><surname>Robertson</surname><given-names>KD</given-names></name></person-group><article-title>Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer</article-title><source>Carcinogenesis</source><year>2006</year><volume>27</volume><fpage>1341</fpage><lpage>1348</lpage><pub-id pub-id-type="pmid">16501252</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgi379</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Caraway</surname><given-names>H</given-names></name><name><surname>Gabrielson</surname><given-names>E</given-names></name><name><surname>Ohmura</surname><given-names>T</given-names></name><name><surname>Fujikane</surname><given-names>T</given-names></name><name><surname>Nishikawa</surname><given-names>N</given-names></name><name><surname>Sogabe</surname><given-names>Y</given-names></name><name><surname>Nojima</surname><given-names>M</given-names></name><name><surname>Sonoda</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Shinomura</surname><given-names>Y</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Tokino</surname><given-names>T</given-names></name></person-group><article-title>Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer</article-title><source>Br J Cancer</source><year>2008</year><volume>98</volume><fpage>1147</fpage><lpage>1156</lpage><pub-id pub-id-type="pmid">18283316</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6604259</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veeck</surname><given-names>J</given-names></name><name><surname>Bektas</surname><given-names>N</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Kristiansen</surname><given-names>G</given-names></name><name><surname>Heindrichs</surname><given-names>U</given-names></name><name><surname>Knuchel</surname><given-names>R</given-names></name><name><surname>Dahl</surname><given-names>E</given-names></name></person-group><article-title>Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours</article-title><source>Breast Cancer Research</source><year>2008</year><volume>10</volume><fpage>R82</fpage><pub-id pub-id-type="pmid">18826564</pub-id><pub-id pub-id-type="doi">10.1186/bcr2151</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Tamura</surname><given-names>G</given-names></name><name><surname>Tsuchiya</surname><given-names>T</given-names></name><name><surname>Sakata</surname><given-names>K</given-names></name><name><surname>Kashiwaba</surname><given-names>M</given-names></name><name><surname>Osakabe</surname><given-names>M</given-names></name><name><surname>Motoyama</surname><given-names>T</given-names></name></person-group><article-title>Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers</article-title><source>Br J Cancer</source><year>2001</year><volume>85</volume><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">11437404</pub-id><pub-id pub-id-type="doi">10.1054/bjoc.2001.1853</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virmani</surname><given-names>AK</given-names></name><name><surname>Rathi</surname><given-names>A</given-names></name><name><surname>Sathyanarayana</surname><given-names>UG</given-names></name><name><surname>Padar</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>CX</given-names></name><name><surname>Cunnigham</surname><given-names>HT</given-names></name><name><surname>Farinas</surname><given-names>AJ</given-names></name><name><surname>Milchgrub</surname><given-names>S</given-names></name><name><surname>Euhus</surname><given-names>DM</given-names></name><name><surname>Gilcrease</surname><given-names>M</given-names></name><name><surname>Herman</surname><given-names>J</given-names></name><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name></person-group><article-title>Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas</article-title><source>Clin Cancer Res</source><year>2001</year><volume>7</volume><fpage>1998</fpage><lpage>2004</lpage><pub-id pub-id-type="pmid">11448917</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ordway</surname><given-names>JM</given-names></name><name><surname>Budiman</surname><given-names>MA</given-names></name><name><surname>Korshunova</surname><given-names>Y</given-names></name><name><surname>Maloney</surname><given-names>RK</given-names></name><name><surname>Bedell</surname><given-names>JA</given-names></name><name><surname>Citek</surname><given-names>RW</given-names></name><name><surname>Bacher</surname><given-names>B</given-names></name><name><surname>Peterson</surname><given-names>S</given-names></name><name><surname>Rohlfing</surname><given-names>T</given-names></name><name><surname>Hall</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Lakey</surname><given-names>N</given-names></name><name><surname>Doerge</surname><given-names>RW</given-names></name><name><surname>Martienssen</surname><given-names>RA</given-names></name><name><surname>Leon</surname><given-names>J</given-names></name><name><surname>McPherson</surname><given-names>JD</given-names></name><name><surname>Jeddeloh</surname><given-names>JA</given-names></name></person-group><article-title>Identification of novel high-frequency DNA methylation changes in breast cancer</article-title><source>PLoS ONE</source><year>2007</year><volume>2</volume><fpage>e1314</fpage><pub-id pub-id-type="pmid">18091988</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0001314</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Ushijima</surname><given-names>T</given-names></name></person-group><article-title>Diagnostic and therapeutic applications of epigenetics</article-title><source>Jpn J Clin Oncol</source><year>2005</year><volume>35</volume><fpage>293</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">15930038</pub-id><pub-id pub-id-type="doi">10.1093/jjco/hyi088</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;ller</surname><given-names>HM</given-names></name><name><surname>Oberwalder</surname><given-names>M</given-names></name><name><surname>Fiegl</surname><given-names>H</given-names></name><name><surname>Morandell</surname><given-names>M</given-names></name><name><surname>Goebel</surname><given-names>G</given-names></name><name><surname>Zitt</surname><given-names>M</given-names></name><name><surname>M&#x000fc;hlthaler</surname><given-names>M</given-names></name><name><surname>Ofner</surname><given-names>D</given-names></name><name><surname>Margreiter</surname><given-names>R</given-names></name><name><surname>Widschwendter</surname><given-names>M</given-names></name></person-group><article-title>Methylation changes in faecal DNA: a marker for colorectal cancer screening?</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>1283</fpage><lpage>1285</lpage><pub-id pub-id-type="pmid">15094274</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16002-9</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>ZH</given-names></name><name><surname>Li</surname><given-names>LH</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>JF</given-names></name></person-group><article-title>Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions</article-title><source>World J Gastroenterol</source><year>2007</year><volume>13</volume><fpage>950</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">17352030</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oberwalder</surname><given-names>M</given-names></name><name><surname>Zitt</surname><given-names>M</given-names></name><name><surname>W&#x000f6;ntner</surname><given-names>C</given-names></name><name><surname>Fiegl</surname><given-names>H</given-names></name><name><surname>Goebel</surname><given-names>G</given-names></name><name><surname>Zitt</surname><given-names>M</given-names></name><name><surname>K&#x000f6;hle</surname><given-names>O</given-names></name><name><surname>M&#x000fc;hlmann</surname><given-names>G</given-names></name><name><surname>Ofner</surname><given-names>D</given-names></name><name><surname>Margreiter</surname><given-names>R</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>HM</given-names></name></person-group><article-title>SFRP2 methylation in fecal DNA-a marker for colorectal polyps</article-title><source>Int J Colorectal Dis</source><year>2008</year><volume>23</volume><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">17639423</pub-id><pub-id pub-id-type="doi">10.1007/s00384-007-0355-2</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roman-Gomez</surname><given-names>J</given-names></name><name><surname>Jimenez-Velasco</surname><given-names>A</given-names></name><name><surname>Agirre</surname><given-names>X</given-names></name><name><surname>Castillejo</surname><given-names>JA</given-names></name><name><surname>Navarro</surname><given-names>G</given-names></name><name><surname>Barrios</surname><given-names>M</given-names></name><name><surname>Andreu</surname><given-names>EJ</given-names></name><name><surname>Prosper</surname><given-names>F</given-names></name><name><surname>Heiniger</surname><given-names>A</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name></person-group><article-title>Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia</article-title><source>Br J Cancer</source><year>2004</year><volume>91</volume><fpage>707</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">15226763</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urakami</surname><given-names>S</given-names></name><name><surname>Shiina</surname><given-names>H</given-names></name><name><surname>Enokida</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>H</given-names></name><name><surname>Kawamoto</surname><given-names>K</given-names></name><name><surname>Kawakami</surname><given-names>T</given-names></name><name><surname>Kikuno</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Majid</surname><given-names>S</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><name><surname>Igawa</surname><given-names>M</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>6989</fpage><lpage>6997</lpage><pub-id pub-id-type="pmid">17145819</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1194</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Shigematsu</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Kubo</surname><given-names>R</given-names></name><name><surname>Motohashi</surname><given-names>S</given-names></name><name><surname>Sekine</surname><given-names>Y</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Iizasa</surname><given-names>T</given-names></name><name><surname>Hiroshima</surname><given-names>K</given-names></name><name><surname>Nakatani</surname><given-names>Y</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>Fujisawa</surname><given-names>T</given-names></name></person-group><article-title>Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>6087</fpage><lpage>6092</lpage><pub-id pub-id-type="pmid">17947472</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0591</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>YY</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Ng</surname><given-names>SS</given-names></name><name><surname>Cheung</surname><given-names>KF</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Rha</surname><given-names>SY</given-names></name><name><surname>Neumann</surname><given-names>U</given-names></name><name><surname>R&#x000f6;cken</surname><given-names>C</given-names></name><name><surname>Ebert</surname><given-names>MP</given-names></name><name><surname>Chan</surname><given-names>FK</given-names></name><name><surname>Sung</surname><given-names>JJ</given-names></name></person-group><article-title>Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer</article-title><source>Cancer</source><year>2009</year><volume>115</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">19051296</pub-id><pub-id pub-id-type="doi">10.1002/cncr.23989</pub-id></citation></ref><ref id="B25"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Sobin</surname><given-names>LH</given-names></name><name><surname>Wittekind</surname><given-names>C</given-names></name><collab>eds</collab></person-group><source>TNM classification of malignant tumors</source><year>1997</year><edition>5</edition><publisher-name>New York: Wiley Liss</publisher-name></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elston</surname><given-names>EW</given-names></name><name><surname>Ellis</surname><given-names>IO</given-names></name></person-group><article-title>Method for grading breast cancer</article-title><source>J Clin Pathol</source><year>1993</year><volume>46</volume><fpage>189</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">8459046</pub-id><pub-id pub-id-type="doi">10.1136/jcp.46.2.189-b</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Remmele</surname><given-names>W</given-names></name><name><surname>Stegner</surname><given-names>HE</given-names></name></person-group><article-title>Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue</article-title><source>Pathologe</source><year>1987</year><volume>8</volume><fpage>138</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">3303008</pub-id></citation></ref><ref id="B28"><citation citation-type="other"><article-title>Ensembl Genome Browser</article-title><ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/index.html"/></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>LC</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>MethPrimer: designing primers for methylation PCRs</article-title><source>Bioinformatics</source><year>2002</year><volume>18</volume><fpage>1427</fpage><lpage>1431</lpage><pub-id pub-id-type="pmid">12424112</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/18.11.1427</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>D</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><article-title>Comprehensive analysis of CpG islands in human chromosomes 21 and 22</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>3740</fpage><lpage>3745</lpage><pub-id pub-id-type="pmid">11891299</pub-id><pub-id pub-id-type="doi">10.1073/pnas.052410099</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Ouchida</surname><given-names>M</given-names></name><name><surname>Tsuji</surname><given-names>T</given-names></name><name><surname>Hanafusa</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><name><surname>Namba</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><name><surname>Shimizu</surname><given-names>K</given-names></name></person-group><article-title>Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells</article-title><source>Gene</source><year>2002</year><volume>282</volume><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">11814687</pub-id><pub-id pub-id-type="doi">10.1016/S0378-1119(01)00838-1</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Graff</surname><given-names>JR</given-names></name><name><surname>Myohanen</surname><given-names>S</given-names></name><name><surname>Nelkin</surname><given-names>BD</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>9821</fpage><lpage>9826</lpage><pub-id pub-id-type="pmid">8790415</pub-id><pub-id pub-id-type="doi">10.1073/pnas.93.18.9821</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galm</surname><given-names>O</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name></person-group><article-title>Methylation-specific polymerase chain reaction</article-title><source>Methods Mol Med</source><year>2005</year><volume>113</volume><fpage>279</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">15968111</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Watkins</surname><given-names>DN</given-names></name><name><surname>Jair</surname><given-names>KW</given-names></name><name><surname>Schuebel</surname><given-names>KE</given-names></name><name><surname>Markowitz</surname><given-names>SD</given-names></name><name><surname>Chen</surname><given-names>WD</given-names></name><name><surname>Pretlow</surname><given-names>TP</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Akiyama</surname><given-names>Y</given-names></name><name><surname>Van Engeland</surname><given-names>M</given-names></name><name><surname>Toyota</surname><given-names>M</given-names></name><name><surname>Tokino</surname><given-names>T</given-names></name><name><surname>Hinoda</surname><given-names>Y</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Herman</surname><given-names>JG</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer</article-title><source>Nat Genet</source><year>2004</year><volume>36</volume><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">15034581</pub-id><pub-id pub-id-type="doi">10.1038/ng1330</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mazieres</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>You</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>AY</given-names></name><name><surname>Mikami</surname><given-names>I</given-names></name><name><surname>Reguart</surname><given-names>N</given-names></name><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name><name><surname>Jablons</surname><given-names>DM</given-names></name></person-group><article-title>Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>4717</fpage><lpage>4720</lpage><pub-id pub-id-type="pmid">15256437</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1389</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>T</given-names></name><name><surname>Miyamoto</surname><given-names>N</given-names></name><name><surname>Oki</surname><given-names>M</given-names></name><name><surname>Nosho</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Endo</surname><given-names>T</given-names></name><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Shinomura</surname><given-names>Y</given-names></name></person-group><article-title>Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers</article-title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>7946</fpage><lpage>7952</lpage><pub-id pub-id-type="pmid">16007117</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1208910</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>JC</given-names></name><name><surname>Kodjabachian</surname><given-names>L</given-names></name><name><surname>Rebbert</surname><given-names>ML</given-names></name><name><surname>Rattner</surname><given-names>A</given-names></name><name><surname>Smallwood</surname><given-names>PM</given-names></name><name><surname>Samos</surname><given-names>CH</given-names></name><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Dawid</surname><given-names>IB</given-names></name><name><surname>Nathans</surname><given-names>J</given-names></name></person-group><article-title>A new secreted protein that binds to Wnt proteins and inhibits their activities</article-title><source>Nature</source><year>1999</year><volume>398</volume><fpage>431</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">10201374</pub-id><pub-id pub-id-type="doi">10.1038/18899</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wissmann</surname><given-names>C</given-names></name><name><surname>Wild</surname><given-names>PJ</given-names></name><name><surname>Kaiser</surname><given-names>S</given-names></name><name><surname>Roepcke</surname><given-names>S</given-names></name><name><surname>Stoehr</surname><given-names>R</given-names></name><name><surname>Woenckhaus</surname><given-names>M</given-names></name><name><surname>Kristiansen</surname><given-names>G</given-names></name><name><surname>Hsieh</surname><given-names>JC</given-names></name><name><surname>Hofstaedter</surname><given-names>F</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Knuechel</surname><given-names>R</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Pilarsky</surname><given-names>C</given-names></name></person-group><article-title>WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer</article-title><source>J Pathol</source><year>2003</year><volume>201</volume><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">14517837</pub-id><pub-id pub-id-type="doi">10.1002/path.1449</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Sakamaki</surname><given-names>T</given-names></name><name><surname>Okano</surname><given-names>H</given-names></name><name><surname>Glazer</surname><given-names>RI</given-names></name></person-group><article-title>Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways</article-title><source>Mol Cell Biol</source><year>2008</year><volume>28</volume><fpage>3589</fpage><lpage>3599</lpage><pub-id pub-id-type="pmid">18362162</pub-id><pub-id pub-id-type="doi">10.1128/MCB.00040-08</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Dacic</surname><given-names>S</given-names></name><name><surname>Landreneau</surname><given-names>RJ</given-names></name><name><surname>Siegfried</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>84</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">18048388</pub-id><pub-id pub-id-type="doi">10.1093/carcin/bgm267</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mizobuchi</surname><given-names>Y</given-names></name><name><surname>Matsuzaki</surname><given-names>K</given-names></name><name><surname>Kuwayama</surname><given-names>K</given-names></name><name><surname>Kitazato</surname><given-names>K</given-names></name><name><surname>Mure</surname><given-names>H</given-names></name><name><surname>Kageji</surname><given-names>T</given-names></name><name><surname>Nagahiro</surname><given-names>S</given-names></name></person-group><article-title>REIC/Dkk-3 induces cell death in human malignant glioma</article-title><source>Neuro Oncol</source><year>2008</year><volume>10</volume><fpage>244</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">18443132</pub-id><pub-id pub-id-type="doi">10.1215/15228517-2008-016</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lodygin</surname><given-names>D</given-names></name><name><surname>Epanchintsev</surname><given-names>A</given-names></name><name><surname>Menssen</surname><given-names>A</given-names></name><name><surname>Diebold</surname><given-names>J</given-names></name><name><surname>Hermeking</surname><given-names>H</given-names></name></person-group><article-title>Functional epigenomics identifies genes frequently silenced in prostate cancer</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>4218</fpage><lpage>4227</lpage><pub-id pub-id-type="pmid">15899813</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4407</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waki</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>G</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Motoyama</surname><given-names>T</given-names></name></person-group><article-title>Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>4128</fpage><lpage>4133</lpage><pub-id pub-id-type="pmid">12821947</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1206651</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>LC</given-names></name><name><surname>Shiina</surname><given-names>H</given-names></name><name><surname>Deguchi</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Okino</surname><given-names>ST</given-names></name><name><surname>Kane</surname><given-names>CJ</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Igawa</surname><given-names>M</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>Age-dependent methylation of ESR1 gene in prostate cancer</article-title><source>Biochem Biophys Res Commun</source><year>2004</year><volume>321</volume><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">15358197</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.06.164</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Kameoka</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Soga</surname><given-names>N</given-names></name><name><surname>Abe</surname><given-names>Y</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name></person-group><article-title>Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2001</year><volume>70</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">11767005</pub-id><pub-id pub-id-type="doi">10.1023/A:1012534724488</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warwick</surname><given-names>J</given-names></name><name><surname>Tabar</surname><given-names>L</given-names></name><name><surname>Vitak</surname><given-names>B</given-names></name><name><surname>Duffy</surname><given-names>SW</given-names></name></person-group><article-title>Time-dependent effects on survival in breast carcinoma: results of 20 years of follow-up from the Swedish Two-County Study</article-title><source>Cancer</source><year>2004</year><volume>100</volume><fpage>1331</fpage><lpage>1336</lpage><pub-id pub-id-type="pmid">15042664</pub-id><pub-id pub-id-type="doi">10.1002/cncr.20140</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrero-Po&#x000fc;s</surname><given-names>M</given-names></name><name><surname>Hac&#x000e8;ne</surname><given-names>K</given-names></name><name><surname>Bouchet</surname><given-names>C</given-names></name><name><surname>Le Doussal</surname><given-names>V</given-names></name><name><surname>Tubiana-Hulin</surname><given-names>M</given-names></name><name><surname>Spyratos</surname><given-names>F</given-names></name></person-group><article-title>Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>4745</fpage><lpage>4754</lpage><pub-id pub-id-type="pmid">11156229</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>JM</given-names></name><name><surname>Dominguez</surname><given-names>G</given-names></name><name><surname>Garcia</surname><given-names>JM</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Villanueva</surname><given-names>MJ</given-names></name><name><surname>Navarro</surname><given-names>F</given-names></name><name><surname>Provencio</surname><given-names>M</given-names></name><name><surname>San Martin</surname><given-names>S</given-names></name><name><surname>Espa&#x000f1;a</surname><given-names>P</given-names></name><name><surname>Bonilla</surname><given-names>F</given-names></name></person-group><article-title>Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>3251</fpage><lpage>3256</lpage><pub-id pub-id-type="pmid">10397273</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lecomte</surname><given-names>T</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Zinzindohoue</surname><given-names>F</given-names></name><name><surname>Micard</surname><given-names>S</given-names></name><name><surname>Landi</surname><given-names>B</given-names></name><name><surname>Blons</surname><given-names>H</given-names></name><name><surname>Beaune</surname><given-names>P</given-names></name><name><surname>Cugnenc</surname><given-names>PH</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name></person-group><article-title>Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis</article-title><source>Int J Cancer</source><year>2002</year><volume>100</volume><fpage>542</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">12124803</pub-id><pub-id pub-id-type="doi">10.1002/ijc.10526</pub-id></citation></ref></ref-list></back></article> 